Clinicopatological variants and risk factors for chronic kidney disease in rheumatoid arthritis
- Authors: Chebotareva N.V.1, Gulyaev S.V.1, Androsova T.V.1, Popova E.N.1, Gurova D.V.1, Novikov P.I.1, Milovanova L.Y.1, Moiseev S.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 92, No 5 (2020)
- Pages: 55-60
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/34603
- DOI: https://doi.org/10.26442/00403660.2020.05.000604
- ID: 34603
Cite item
Full Text
Abstract
Recent studies have shown a high risk of chronic kidney disease and associated cardiovascular complications in patients with rheumatoid arthritis (RA), which determines the prognosis. However, the prevalence of chronic kidney disease (CKD) in RA has not been established in the Russians.
Aim. Study was to examine the prevalence, risk factors and histological variants of CKD in RA.
Materials and methods. 180 patients with rheumatoid arthritis were observed in the Tareev clinic of nephrology, for the period from 2014 to 2019 years. Age, gender, duration of RA, drug therapy, ESR, CRP, DAS28, renal function, proteinuria, histological variants were analyzed. Of the common population risk factors for CKD arterial hypertension, weight index, serum lipids and glucose levels were also assessed.
Results. The prevalence of CKD in RA was 19.7%. Age, presence and stage of arterial hypertension, an increase in body mass index, as well as high rates of disease activity – ESR, CRP, DAS28 score and duration of RA were risk factors of CKD in RA. Age, duration of the disease, stage of AH and hypercholesterolemia were risk factors in multifactorial regression analysis. Amyloidosis was the most common histologic pattern (50.0%), followed by chronic glomerulonephritis (30.4%) and tubulo-interstitial nephritis (19.6%). Among chronic glomerulonephritis mesangial glomerulonephritis was the most frequent. Renal amyloidosis was associated with a duration of RA, presence of systemic symptoms and CRP level. An isolated decrease in GFR of less than 60 ml/min was detected in 31 (36.0%) out of 86 patients.
Сonclusion. The risk factors for CKD in patients with RA are activity and duration of the disease In addition to common population factors. Amyloidosis was the most common histologic pattern associated with duration of RA and inflammatory proteins levels.
Full Text
##article.viewOnOriginalSite##About the authors
N. V. Chebotareva
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0003-2128-8560
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowS. V. Gulyaev
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0001-6138-4333
к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowT. V. Androsova
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0002-9951-126X
к.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowE. N. Popova
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0001-5164-4621
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowD. V. Gurova
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0001-8232-3679
студентка
Russian Federation, MoscowP. I. Novikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0003-0148-5655
к.м.н., зав. отд-нием ревматологии
Russian Federation, MoscowL. Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
ORCID iD: 0000-0002-5599-0350
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowS. V. Moiseev
Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
д.м.н., проф., зав. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowReferences
- Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206-13. doi: 10.1053/j.ajkd.2013.08.010
- Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021
- Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под. ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; с. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Rheumatology. National Guide. Nasonov EL, Nasonova VA, ed. Moscow: GEOTAR-Media, 2008; p. 290-331 (In Russ.)].
- Tokoroyama T, Ando M, Setoguchi K, et al. Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant. 2017;32:2035-42. doi: 10.1093/ndt/gfw315
- Kim HW, Lee CK, Cha HS, et al. Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int. 2015;35(4):727-34. doi: 10.1007/s00296-014-3146-4
- Оранский С.П. Хроническая болезнь почек при ревматоидном артрите: ассоциация с сердечно-сосудистым риском. Фундаментальные исследования. 2013;12:285-8 [Oranskij SP. Hronicheskaya bolezn pochek pri revmatoidnom artrite: associaciya s serdechno-sosudistym riskom. Fundamentalnye issledovaniya. 2013;12:285-8 (In Russ.)]. http://www.fundamental-research.ru/ru/article/view?id=33321
- Батюшин М.М., Выставкина Е.А. Факторы риска развития и прогрессирования хронической болезни почек у больных ревматоидным артритом. Современные проблемы науки и образования. 2011;5 [Batyushin MM, Vystavkina EA. Faktory riska razvitiya i progressirovaniya hronicheskoj bolezni pochek u bolnyh revmatoidnym artritom. Sovremennye problemy nauki i obrazovaniya. 2011;5 (In Russ.)]. http://www.science-education.ru/ru/article/view?id=4871
- Саркисова И.А., Рамеев В.В., Козловская Л.В. Ревматоидный артрит как основная причина развития АА-амилоидоза. Клиническая геронтология. 2009;15(2):14-20 [Sarkisova IA, Rameev VV, Kozlovskaya LV. Revmatoidnyj artrit kak osnovnaya prichina razvitiya AA-amiloidoza. Klinicheskaya gerontologiya. 2009;15(2):14-20 (In Russ.)].
- Саркисова И.А., Рамеев В.В., Козловская Л.В. Факторы риска развития и прогрессирования АА-амилоидоза у больных ревматоидным артритом. Нефрология и диализ. 2007;9(3):346 [Sarkisova IA, Rameev VV, Kozlovskaya LV. Faktory` riska razvitiya i progressirovaniya AA-amiloidoza u bolnykh revmatoidnym artritom. Nefrologiya i dializ. 2007;9(3):346 (In Russ.)].
- Саркисова И.А., Рамеев В.В., Варшавский В.А. и др. Особенности течения АА-амилоидоза у больных ревматоидным артритом. Терапевтический архив. 2006; 78(5):31-6 [Sarkisova IA, Rameev VV, Varshavskij VA, et al. Osobennosti techeniya AA-amiloidoza u bol`ny`kh revmatoidny`m artritom. Therapeutic Archive. 2006;78(5):31-6 (In Russ.)].
- Góis M, Carvalho F, Sousa H, et al. Renal involvement in rheumatoid arthritis: analysis of 53 renal biopsies. Port J Nephrol Hypert. 2017;31(1):25-30.
- Ребров А.П., Тяпкина М.А., Волошинова Е.В. Субклиническое поражение почек у пациентов с ревматоидным артритом. Лечащий врач. 2012;4:40-2 [Rebrov AP, Tyapkina MA, Voloshinova EV. Subclinical failure of kidneys in patients with rheumatoid arthritis. Lechashchij vrach. 2012;4:40-2 (In Russ.)].
- Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек у больных ревматоидным артритом. Сибирский медицинский журнал. 2007;7:90-2 [Kiseleva AG, Orlova GM, Berdnikova IA, Fereferova NM. Chronic kidney disease in rheumatoid arthritis patients. Sibirskij medicinskij zhurnal, 2007;7:90-2 (In Russ.)].
- Kochi M, Kohagura K, Shiohira Y, et al. Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis. PLoS One. 2016;11(8):e0160225. doi: 10.1371/journal.pone.0160225
- Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231-8. doi: 10.1038/ki.2011.283
- Nakahara C, Kanemoto K, Saito N, et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol. 2001;55(5):365-70.
- Schwedler SB, Guderian F, Dämmrich J, et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant. 2003;18(11):2300-7. doi: 10.1093/ndt/gfg407
- Li ZI, Chung AC, Zhou L, et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Lab Invest. 2011;91(6):837-51. doi: 10.1038/labinvest.2011.42
- Galarraga B, Khan F, Kumar P, et al. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1780-4. doi: 10.1093/rheumatology/ken386
- Tapia E, Sánchez-González DJ, Medina-Campos ON, et al. Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria. Am J Physiol Renal Physiol. 2008;295(5):F1431-9. doi: 10.1152/ajprenal.90201.2008
- Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46:658-63. doi: 10.1136/ard.46.9.658
- Toblli JE, Bevione P, Di Gennaro F, et al. Understanding the mechanisms of proteinuria: therapeutic implications. Int J Nephrol. 2012;546039. doi: 10.1155/2012/546039
- Hemmelgarn BR, Manns BJ, Lloyd A, et al; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. J Am Med Assoc. 2010;303(5):423-9. doi: 10.1001/jama.2010.39
- Möller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015;74(4):718-23. doi: 10.1136/annrheumdis-2013-204078
- Daoussis D, Panoulas VF, Antonopoulos I, et al. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:517-21. doi: 10.1136/ard.2008.105049
- Salomon MI, Gallo G, Poon TP, et al. The kidney in rheumatoid arthritis. Nephron. 1974;12:297310.
- Ramirez G, Lambert R, Bloomer A. Renal pathology in patients with rheumatoid arthritis. Nephron. 1981;29:124-6. doi: 10.1159/000182132
- Yoshida A, Morozumi K, Suganuma T, et al. Clinicopathological study of nephropathy in patients with rheumatoid arthritis. Ryumachi. 1991;31:14-21.
- Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arth Rheum. 1995;38(2):242-7. doi: 10.1002/art.1780380213
- Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154-60.
- Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol. 2002;12:148-54. doi: 10.3109/s101650200025
- Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377-84. doi: 10.1016/0002-9343(84)90654-5
- Sumida K, Molnar MZ, Potukuchi PK, et al. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93(5):1207-16. doi: 10.1016/j.kint.2017.11.025
- Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008;59(12):1821-4. doi: 10.1002/art.24308
- Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):303-5. doi: 10.1136/ard.2004.023119
- Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1):83-6.
- Immonen K, Finne P, Gronhagen-Riska C, et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol. 2009;38:403. doi: 10.3109/13506129.2010.549252
- Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028
- Nakamura T, Higashi S, Tomoda K, et al. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2012;51(11):2064-9. doi: 10.1093/rheumatology/kes190
- Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019-24. doi: 10.1002/art.11163
Supplementary files
![](/img/style/loading.gif)